Abstract
The frequency of antibiotic resistance among common human and animal pathogens has continued to rise despite concerted efforts to improve antibiotic use and increase awareness of antibiotic resistance among providers and consumers of these valuable agents (1). Among hospital and community acquired infections, there are more than a dozen organisms whose multidrug resistance means that some individuals may contract infections for which there is only one drug with which to treat, or even in some instances, no drugs at all (Table 1). Among the latter organisms are the hospital acquired vancomycin-resistant Enterocoecus, Pseudomonas aeruginosa and Acinetobacter baumanii. The methicillin-resistant Staphylococcus aureus strains which have recently emerged with chromosomally-specified decreased susceptibility to vancomycin are also potentially the ones that could eventually be untreatable. In the community, Mycobacterium tuberculosis is a major problem with the Pneumococcus not far behind, especially as cephalosporin resistance rises and the use of this life-saving drug is lost. Vancomycin is the only drug left, used with a cephalosporin, to treat meningitis caused by the very common invasive pneumococcus.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. B. Levy, The Challenge of Antibiotic Resistance, Scientific American 278:32–39 (1998).
S. B. Levy. The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle, Plenum, New York (1992).
L.M. McMurry, R. Petrucci and S.B. Levy, Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in E. coli. Proc. Natl. Acad. Sci. USA 77:3974–3977 (1980).
S.P. Cohen, D.C. Hooper, J.S. Wolfson, K.S. Souza, L.M. McMurry, and S.B. Levy, Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob. Agents Chemother 32:1187–1191 (1988).
S.B. Levy, Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36:695–703(1992).
H. Nikaido, Prevention of drug access to bacterial targets: permeability barriers and active efflux, Science 264:382–388(1994).
V. Burdett, Streptococcal tetracycline resistance mediated at the level of protein synthesis, J. Bact 165:564–569(1986).
B.P. Rosen and J.S. McClees, Active transport of calcium in inverted membrane vesicles of Escherichia coli. Proc. Natl. Acad. Sci. USA 71:5042–5046 (1974).
M.A. Kaneko, Yamaguchi and T. Sawai, Energetics of tetracycline efflux system encoded by Tn10 in Escherichia coli. FEBS Letters 193:194–197 (1985).
A. Yamaguchi, T. Udagawa and T. Sawai, Transport of divalent cations with tetracycline as mediated by the transposon Tn10-encoded tetracycline resistance protein, J Biol. Chem 265:4809–4813 (1990).
S.B. Levy and L. McMurry, Detection of an inducible membrane protein associated with R-factor-medi-ated tetracycline resistance, Biochem. Biophys. Res. Comm 56:1060–1068 (1974).
M.S. Curiale and S.B. Levy, Two complementation groups mediate tetracycline resistance determined by Tn10. J. Bacteriol 151:209–215(1982).
M.S. Curiale, L.M. McMurry and S.B. Levy, Intracistronic complementation of the tetracycline resistance membrane protein specified by Tn10. J. Bacteriol 157:211–217(1984).
R.A. Rubin and S.B. Levy, Interdomain hybrid Tet proteins confer tetracycline resistance only when derived from more closely related members of the tet gene family, J. Bacteriol 172:2303–2312(1990).
R.K. Hickman, L. M. McMurry and S. B. Levy, Overproduction and purification of the Tn10-specified inner membrane tetracycline resistance protein Tet using fusions to β-galactosidase, Molec. Microbiol 4:1241–1251 (1990).
M.L. Aldema, L.M. McMurry, A.R. Walmsley and S.B. Levy, Purification of the Tn10-specified tetracycline efflux antiporter TetA in a native state as a polyhistidine fusion protein, Molec. Microb 19:187–195 (1996).
C. Saraceni-Richards and S.B. Levy, unpublished.
Y. Someya, Y. Moriyama, M. Futai, T. Sawai and A. Yamaguchi, Reconstitution of the metal-tetracy-cline/H+ antiporter of Escherichia coli in proteoliposomes including F0F1-ATPase, FEBS Letters 374:72–76 (1995).
L.M. McMurry and S.B. Levy, The N-terminal half of the Tn10-encoded tetracycline efflux protein TetA contains a functional dimerization domain, J. Biol. Chem 276:22752–22757 (1995).
M.L. Nelson, B.H. Park, J.S. Andrews, V.A. Georgian, R.C. Thomas and S.B. Levy, Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxy tetracyclines, J. Med. Chem 36:370–377(1993).
M.L. Nelson, B.H. Park and S.B. Levy, Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on growth of tetracycline resistant bacteria, J. Med. Chem 37:1355–1361 (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Levy, S.B., Nelson, M. (1998). Reversing Tetracycline Resistance. In: Rosen, B.P., Mobashery, S. (eds) Resolving the Antibiotic Paradox. Advances in Experimental Medicine and Biology, vol 456. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4897-3_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4897-3_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7220-2
Online ISBN: 978-1-4615-4897-3
eBook Packages: Springer Book Archive